Chunmei Shi

Fujian Medical University — China

Medicine · Health Sciences

8h-index166citations26works3.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(7), Medical Imaging and Pathology Studies(5), Lung Cancer Treatments and Mutations(4), Gastric Cancer Management and Outcomes(4), Cancer Genomics and Diagnostics(4)

Publications26 total

Core decompression combined with allogeneic fibular grafting for refractory transient osteoporosis of the hip: a case report and literature review
BMC Surgery·2025Open Access
The impact of social and psychological support on patients with varying degrees of severity of chronic obstructive pulmonary disease
Frontiers in Medicine·2025· 2 citedOpen Access
The Potential Effect of Plant Based Antioxidants in Breast Cancer Prevention and Treatment
Indian Journal of Pharmaceutical Education and Research·2025
14eP Sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in Chinese patients (pts) with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (mBC): Sub analysis of the results from the phase III EVER-132-002 study
ESMO Open·2025Open Access
Proteomics and Phosphoproteomics Characteristics of the Rhesus Macaque Lung Infected With Original SARS‐CoV‐2, Delta, and Omicron Variants
Journal of Medical Virology·2025
Dynamic Molecular Changes in Brain, Lung, and Heart of Hamsters Infected With SARS‐CoV‐2: Insights From a Severe and Recovery Phase Model
Journal of Medical Virology·2025
Why do travelers discontinue using integrated ride-hailing platforms? The role of perceived value and perceived risk
Humanities and Social Sciences Communications·2025· 7 citedOpen Access
Exploring determinants of travelers’ discontinuance behavioral intention on integrated ride-hailing services: A perspective on perceived risk
Journal of Retailing and Consumer Services·2024· 15 cited
Hallmarks of cancer in patients with heart failure: data from BIOSTAT-CHF
Cardio-Oncology·2024· 3 citedOpen Access
The genetic status and rescue measure for a geographically isolated population of Amur tigers
Scientific Reports·2024· 8 citedOpen Access
1057P Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
Annals of Oncology·2023Open Access
Risk factors and predictors of urogenous sepsis after percutaneous nephrolithotomy for idiopathic calcium oxalate nephrolithiasis
Translational Andrology and Urology·2023· 8 citedOpen Access
Data from Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study
2023Open Access
Supplementary Data from Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study
2023Open Access
Data from Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study
2023Open Access
Supplementary Data from Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study
2023Open Access
Supplementary Data from Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study
2023Open Access
Supplementary Data from Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study
2023Open Access
Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.
Journal of Clinical Oncology·2022· 5 cited
A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors.
Journal of Clinical Oncology·2021· 14 cited
page 1 of 2Next →

Frequent Co-authors

Yuankai Shi(7), Qiqing Cai(7), Yu Jiang(7), Minghong Bi(7), Baocheng Wang(7), Yuhong Zhou(7), Guowen Wang(7), Hongyan Ying(7), Zhiwei Tao(7), Gang Huang(6), Qian Guo(6), Qiang Chen(4), Chao Gao(4), Ye Xu(3), Aimin Zang(3), Yunong Gao(3), Quanli Gao(3), Dong Wang(3), Ying Yuan(3), Jieer Ying(3)